Radiopharmaceuticals as Novel Immune System Tracers

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigms for multiple cancers. However, ICI therapy often fails to generate measurable and sustained antitumor responses, and clinically meaningful benefits remain limited to a small proportion of overall patients. A major obstacle...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridge, Natalie A., Rajkumar-Calkins, Anne, Dudzinski, Stephanie O., Kirschner, Austin N., Newman, Neil B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Special Collection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486425/
https://www.ncbi.nlm.nih.gov/pubmed/36148374
http://dx.doi.org/10.1016/j.adro.2022.100936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486425/
https://www.ncbi.nlm.nih.gov/pubmed/36148374
http://dx.doi.org/10.1016/j.adro.2022.100936

Ejemplares similares